Dongxin Wang received his Ph.D. in Biomedical Engineering at the University of Science and Technology of China in 2022. His research focuses on gene therapies, especially using AAV vectors to treat Duchenne muscular dystrophy (DMD). His primary research interests include engineering novel gene therapy vectors, quantitative evaluation of the immune response in muscle gene therapy, genome editing, gene-replacement therapy, and the structure-function relationship of dystrophin in rodents and large mammals.
